Dr. Tiffany A. Traina, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Js Weill Medical College, Cornell University (1999)
- Years since graduation
- 27
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 115
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1999Medical school: Js Weill Medical College, Cornell University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 219019
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Solid Tumor Group (234 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 115
- Services billed
- 286
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 220 | 106 |
| New patient office or other outpatient visit, 60-74 minutes | 35 | 35 |
| Established patient office or other outpatient visit, 40-54 minutes | 16 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in New York, NY | 57 |
| Exemestane | 12 |
| Tamoxifen Citrate Other prescribers in New York, NY | 12 |
| Ibrance (palbociclib) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 42 payments worth $75,011 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $18,190 |
|---|---|
| BioNTech SE | $13,500 |
| Gilead Sciences, Inc. | $13,368 |
| AstraZeneca UK Limited | $9,295 |
| Genentech, Inc. | $7,333 |
| Stemline Therapeutics Inc. | $6,717 |
| Corcept Therapeutics | $4,049 |
| Merck Sharp & Dohme LLC | $2,560 |
| Consulting Fee | $70,143 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $4,000 |
| Travel and Lodging | $653 |
| Food and Beverage | $216 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| BioNTech SE Oct 8, 2025 | Consulting Fee | $6,750 |
| AstraZeneca UK Limited Dec 12, 2025 | Consulting Fee DATROWAY · Oncology Company’s descriptionResearch Related Service | $6,150 |
| BioNTech SE Oct 8, 2025 | Consulting Fee | $4,725 |
| Stemline Therapeutics Inc. Oct 9, 2025 | Consulting Fee Orserdu · Oncology | $4,680 |
| AstraZeneca Pharmaceuticals LP May 2, 2025 | Consulting Fee DATROWAY · Oncology Company’s descriptionResearch Related Service | $4,110 |
| Corcept Therapeutics Dec 24, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,000 |
| AstraZeneca Pharmaceuticals LP Nov 11, 2025 | Consulting Fee DATROWAY · Oncology | $3,690 |
| AstraZeneca Pharmaceuticals LP Sep 25, 2025 | Consulting Fee ENHERTU · Oncology | $3,280 |
| AstraZeneca Pharmaceuticals LP Nov 13, 2025 | Consulting Fee DATROWAY · Oncology | $3,280 |
| Gilead Sciences, Inc. Dec 19, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4238620;SAP;11024743 | $3,050 |
All 37 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Corcept Therapeutics Dec 24, 2025 | Compensation for services other than consulting (speaking, faculty) | $4,000 |
| Gilead Sciences, Inc. Dec 19, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4238620;SAP;11024743 | $3,050 |
| AstraZeneca Pharmaceuticals LP Dec 16, 2025 | Consulting Fee ENHERTU · Oncology Company’s descriptionResearch Related Service | $1,640 |
| AstraZeneca UK Limited Dec 12, 2025 | Consulting Fee DATROWAY · Oncology Company’s descriptionResearch Related Service | $6,150 |
| Gilead Sciences, Inc. Nov 30, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4289909;GTF;11024743 | $725 |
| Gilead Sciences, Inc. Nov 24, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4252169;GTF;11024743 | $725 |
| BioNTech SE Nov 20, 2025 | Consulting Fee | $2,025 |
| AstraZeneca Pharmaceuticals LP Nov 13, 2025 | Consulting Fee DATROWAY · Oncology | $3,280 |
| AstraZeneca UK Limited Nov 13, 2025 | Consulting Fee | $2,460 |
| Merck Sharp & Dohme LLC Nov 12, 2025 | Consulting Fee | $1,280 |
| AstraZeneca Pharmaceuticals LP Nov 11, 2025 | Consulting Fee DATROWAY · Oncology | $3,690 |
| Gilead Sciences, Inc. Nov 6, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4267674;VEM US;11024743 | $1,240 |
| Gilead Sciences, Inc. Oct 23, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4253564;VEM US;11024743 | $1,820 |
| AstraZeneca UK Limited Oct 20, 2025 | Consulting Fee DATROWAY · Oncology Company’s descriptionResearch Related Service | $685 |
| Gilead Sciences, Inc. Oct 18, 2025 | Travel and Lodging Trodelvy · ONC · travel to Foster City, CA · in-kind Company’s description;4253436;VEM US;11024743 | $634 |
| Stemline Therapeutics Inc. Oct 9, 2025 | Consulting Fee Orserdu · Oncology | $4,680 |
| BioNTech SE Oct 8, 2025 | Consulting Fee | $6,750 |
| BioNTech SE Oct 8, 2025 | Consulting Fee | $4,725 |
| AstraZeneca Pharmaceuticals LP Sep 25, 2025 | Consulting Fee ENHERTU · Oncology | $3,280 |
| Gilead Sciences, Inc. Sep 25, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4289905;GTF;11024743 | $725 |
| Gilead Sciences, Inc. Aug 28, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4252159;GTF;11024743 | $1,450 |
| Gilead Sciences, Inc. Aug 28, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4252167;GTF;11024743 | $725 |
| Gilead Sciences, Inc. Aug 19, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4289907;GTF;11024743 | $725 |
| Merck Sharp & Dohme LLC Aug 13, 2025 | Consulting Fee | $1,280 |
| Genentech, Inc. Jul 28, 2025 | Consulting Fee | $1,900 |
| Stemline Therapeutics Inc. Jul 25, 2025 | Consulting Fee Orserdu · Oncology | $780 |
| Stemline Therapeutics Inc. Jul 25, 2025 | Consulting Fee Orserdu · Oncology | $390 |
| Gilead Sciences, Inc. Jul 16, 2025 | Consulting FeeCompany’s description;4275678;VEM US;11024743 | $1,450 |
| AstraZeneca Pharmaceuticals LP Jun 25, 2025 | Consulting Fee | $820 |
| Genentech, Inc. Jun 11, 2025 | Consulting Fee | $858 |
| Gilead Sciences, Inc. May 30, 2025 | Travel and Lodging travel to Chicago, IL Company’s description;4275670;VEM US;11024743 | $18.60 |
| Stemline Therapeutics Inc. May 23, 2025 | Consulting Fee Orserdu · Oncology | $780 |
| Genentech, Inc. May 15, 2025 | Consulting Fee | $1,710 |
| AstraZeneca Pharmaceuticals LP May 2, 2025 | Consulting Fee DATROWAY · Oncology Company’s descriptionResearch Related Service | $4,110 |
| AstraZeneca Pharmaceuticals LP Apr 11, 2025 | Consulting Fee DATROWAY · Oncology | $1,370 |
| Genentech, Inc. Feb 10, 2025 | Consulting Fee | $1,710 |
| Genentech, Inc. Jan 22, 2025 | Consulting Fee | $1,155 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $656,495 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurren…
AstraZeneca Pharmaceuticals LP - BNT327-02
BioNTech SE - An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Astellas Pharma Global Development - A phase iii multicenter randomized open label study comparing atezolizumab anti pd L1 antibody
Hoffmann-la Roche Limited
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.